Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078349" target="_blank" >RIV/65269705:_____/23:00078349 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/23:10471795
Result on the web
<a href="https://www.nature.com/articles/s41375-023-02008-6" target="_blank" >https://www.nature.com/articles/s41375-023-02008-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-023-02008-6" target="_blank" >10.1038/s41375-023-02008-6</a>
Alternative languages
Result language
angličtina
Original language name
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
Original language description
Patients with polycythemia vera (PV), an incurable Philadelphia-negative myeloproliferative neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution to myelofibrosis or acute myeloid leukemia [1, 2]. Clinical management of PV has primarily addressed the thrombotic risk, whereas prevention of disease progression remains a significant unmet need [3]. Interferon alfa is recognized as a disease-modifying treatment for PV that may reduce the risk of myelofibrotic progression and potentially prolong overall survival according to retrospective data, but prospective studies to confirm these findings have been lacking [4]. Final results from the large PROUD-PV trial and its extension CONTINUATION-PV are now available comparing ropeginterferon alfa-2b (BESREMi(R)) with hydroxyurea or best available treatment (BAT) over a total of 6 years.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia
ISSN
0887-6924
e-ISSN
1476-5551
Volume of the periodical
37
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
4
Pages from-to
2129-2132
UT code for WoS article
001063663500003
EID of the result in the Scopus database
2-s2.0-85168859320